A practical reference on c-Met receptor: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-10-15 and is reviewed periodically as new material appears.
Regulatory status varies by country, and dihexa is not widely approved as a medicine. In many jurisdictions it is treated as a research chemical, which limits its legal sale, possession, and human use. Products marketed online may lack verified purity or identity, and labels can be inaccurate. Researchers typically source material from suppliers that provide analytical documentation and follow institutional safety rules. Open questions remain about long-term stability, metabolite formation, and human pharmacokinetics.
Dihexa is typically supplied as a lyophilized powder for laboratory research. Lyophilization removes water and improves stability during transport and storage. The solid is commonly stored at -20 °C or lower, desiccated, and protected from light. Repeated freeze-thaw cycles and exposure to moisture can degrade peptides, so aliquoting and sealed containers are standard practice in most laboratory settings. These handling measures apply to research-grade material and do not imply clinical suitability.
Identity checks for dihexa usually rely on mass spectrometry and chromatographic purity analysis. A lyophilized powder is the common supplied form, and it may appear as a white to off-white solid. Aqueous solubility is limited, so laboratory work often uses an organic solvent such as dimethyl sulfoxide to prepare stock solutions. Because the peptide is not a standard pharmaceutical product, exact specifications can vary between suppliers. Certificates of analysis may accompany a batch, but they are not equivalent to regulatory approval.
Dihexa is a synthetic peptide whose structure is modeled on angiotensin IV. Its chemical name often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, though vendor and publication naming can differ. The molecule combines a short amino acid sequence with a hexanoic acid group and an amide terminus. It is classed as a small research peptide rather than a conventional drug. Databases may list it under several synonyms, so matching names are important when comparing sources.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Typical lyophilized research form. |
| Solubility | Soluble in DMSO; limited in water | Depends on purity and salt form. |
| Storage temperature | -20 °C or lower | Desiccated and protected from light. |
| Analytical method | RP-HPLC and LC-MS | Common for purity and identity. |
| Regulatory status | Research chemical in many countries | Not widely approved as a medicine. |
Regulatory and commercial contexts differ from clinical medicine. Dihexa is not approved as a drug by major agencies, and no published human trials establish its safety or efficacy. It is often sold as a research chemical labeled for laboratory use only. Suppliers may provide certificates of analysis, but purity and identity depend on the specific batch. Legal status varies by country and may treat such compounds as unapproved substances for human consumption.
Dihexa is a synthetic peptidomimetic derived from angiotensin IV, a naturally occurring peptide fragment. It was created as a research compound to explore central nervous system signaling rather than as an approved therapeutic. Early work described it as a small, orally available molecule in rodent studies. Its structure combines tyrosine, isoleucine, and aminohexanoic acid components with a hexanoic acid cap. The compound is commonly referred to by the research code PNB-0408.
Development of dihexa followed from studies on angiotensin IV analogs and their effects on learning and memory. Researchers sought compounds with improved metabolic stability and brain penetration compared with natural peptides. In preclinical reports, dihexa was associated with changes in synaptic connectivity and performance on spatial tasks. These findings generated interest in its potential as a cognitive research tool. The work remains largely preclinical, and independent replication has been limited.
Chemically, dihexa is a short peptide-like molecule with nonstandard components. Its structure includes tyrosine and isoleucine residues linked to a hexanoic acid group and an aminohexanoic amide segment. This design distinguishes it from endogenous angiotensin IV, though the two are discussed together because of shared origins. Published summaries classify it as a small synthetic peptide with lipophilic features that may influence how it crosses biological barriers in experimental systems. Exact conformational details depend on the specific salt or free base form.
Regulatory treatment varies by country. Dihexa does not appear in major pharmacopeias as a licensed therapeutic substance. Suppliers may use labels such as research use only or not for human consumption. Such labels reflect legal and quality-control boundaries rather than evidence of clinical benefit. Importation, possession, and sale can be restricted depending on local laws, and enforcement focuses on claims, distribution channels, and product categories. These rules can change, and they differ from rules for approved medicines.
Dihexa is a synthetic peptide studied in preclinical neuroscience. It is often described as an angiotensin IV analog or derivative. The compound also appears under research codes such as PNB-0408 and N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. It is not an approved drug, and it is not a conventional vitamin or nutrient. In many jurisdictions, material sold as dihexa is handled as a research chemical rather than a medicine or supplement. This classification affects how the material is labeled and distributed.
In animal research, dihexa has been administered through several routes, and reports describe improved performance on spatial learning and memory tasks in rodents. These results are frequently cited in discussions of nootropic compounds. However, species differences, small sample sizes, and varied testing protocols limit how far the findings can be generalized. No large randomized controlled trials in humans have established efficacy or long-term safety. Claims about human cognitive enhancement therefore remain speculative, and the compound is best described as an experimental laboratory substance rather than a proven therapeutic or supplement.
Dihexa is a synthetic compound studied in laboratory and animal models for effects on synaptic connectivity and cognitive performance. It is often described as a peptide analog because its structure incorporates amino acid residues linked to a hexanoic acid group. The molecule is not a naturally occurring human hormone or neurotransmitter. Its name appears in research literature and online discussions, but it has not been approved as a medicine by major regulatory agencies. Most information comes from preclinical experiments rather than controlled human trials.
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
== Risk factors affecting food distribution and examples of failed policy == Prominent risk factors that can affect the food distribution within a society include war, economic failure, political instability, and weather conditions. Each of these factors affects individual groups of people differently, but all share the common attribute of being detrimental to local food distribution and food systems. Two prominent examples of risk factors' negative effect on a society's food distribution system are the situation in Japan during World War II and Africa during the late 1970s and early 1980s.
This ended relations between Mexico and Germany, which had been weakening since the British commercial blockade against the Axis. Simultaneously, Mexico resumed diplomatic relations with the United Kingdom, which had been broken since the oil expropriation of 1938.
== Biography == Barrett was born in 1963 in Toronto, Ontario, Canada, to a working poor family and was the first member of her extended family to attend university. After graduating from the University of Toronto with honors, she pursued a Ph.D. in clinical psychology at the University of Waterloo with the goal of becoming a therapist, until a frustrating puzzle sidetracked her from a clinical career. As a graduate student, she failed eight times to replicate a simple experiment, finally realizing that her seeming failed attempts were, in fact, successfully replicating a previously undiscovered phenomenon. The resulting research direction became her life's work: understanding the nature of emotion in the brain. Following a clinical internship at the University of Manitoba Medical School, she held professorships in psychology at Penn State University, Boston College, and Northeastern University.[1] Over two decades, she transitioned from clinical psychology into social psychology, psychophysiology, cognitive science, and cognitive neuroscience. Barrett is most inspired by William James, Wilhelm Wundt, and Charles Darwin. In 2019–2020, she served as president of the Association for Psychological Science. From 2018–2025, she was ranked in the top one percent of the most-cited scientists in the world over a ten-year period. In addition to academic work, Barrett has written two science books for the public, How Emotions are Made (2017) and Seven and a Half Lessons About the Brain (2020), and her TED talk was among the 25 most popular worldwide in 2018.
=== Rearrangement reactions === Rearrangement reactions are fragmentation reactions that form new bonds producing an intermediate structure before cleavage. One of the most studied rearrangement reaction is the McLafferty rearrangement / γ-hydrogen rearrangement. This occurs in the radical cations with unsaturated functional groups, like ketones, aldehydes, carboxylic acids, esters, amides, olefins, phenylalkanes. During this reaction, γ-hydrogen will transfer to the functional group at first and then subsequent α, β-bond cleavage of the intermediate will take place. Other rearrangement reactions include heterocyclic ring fission (HRF), benzofuran forming fission (BFF), quinone methide (QM) fission or Retro Diels-Alder (RDA).
=== Impact on nutrition === The introduction of refrigeration allowed for the hygienic handling and storage of perishables, and as such, promoted output growth, consumption, and the availability of nutrition. The change in our method of food preservation moved us away from salts to a more manageable sodium level. The ability to move and store perishables such as meat and dairy led to a 1.7% increase in dairy consumption and overall protein intake by 1.25% annually in the US after the 1890s. People were not only consuming these perishables because it became easier for they themselves to store them, but because the innovations in refrigerated transportation and storage led to less spoilage and waste, thereby driving the prices of these products down. Refrigeration accounts for at least 5.1% of the increase in adult stature (in the US) through improved nutrition, and when the indirect effects associated with improvements in the quality of nutrients and the reduction in illness is additionally factored in, the overall impact becomes considerably larger. Recent studies have also shown a negative relationship between the number of refrigerators in a household and the rate of gastric cancer mortality.
Sources: en.wikipedia.org
== Further reading == Cook, E.M, and DuMont, H.D. (1991) Process Drying Practice, McGraw-Hill, Inc., ISBN 0-07-012462-0 Keey, R.B., (1992). Drying of Loose and Particulate Materials 1st ed., Taylor & Francis, ISBN 0-89116-878-8 Nutritional evaluation of food processing second edition (1975), Robert S. Harris, Ph.D. and Endel Karmas Ph.D. (eds) Filková, I., & Mujumdar, A. S. (2020). Industrial spray drying systems. In Handbook of industrial drying (pp. 263-307). CRC Press. Jafari, S. M., Arpagaus, C., Cerqueira, M. A., & Samborska, K. (2021). Nano spray drying of food ingredients; materials, processing and applications. Trends in Food Science & Technology, 109, 632-646. Klimša, V., Ruphuy, G., Jonáš, J., Mašková, L., Kašpar, O., Žvátora, P., & Štěpánek, F. (2023). Spray drying robot for high-throughput combinatorial fabrication of multicomponent solid dispersions. Powder Technology, 428, 118872.
=== Incandescent lamps === 'Black light' incandescent lamps are also made from an incandescent light bulb with a filter coating which absorbs most visible light. Halogen lamps with fused quartz envelopes are used as inexpensive UV light sources in the near UV range, from 400 to 300 nm, in some scientific instruments. Due to its black-body spectrum a filament light bulb is a very inefficient ultraviolet source, emitting only a fraction of a percent of its energy as UV, as explained by the black body spectrum.
== Buildings == The department spans three buildings. The main departmental building, finished in 1927 (architect Edward Warren) is situated on Tennis Court Road and the nearby Molteno Institute. Both are situated on the Downing Site in central Cambridge. The third location is part of the main hospital building at Addenbrooke's Hospital on the Cambridge Biomedical Campus.
In October 2023, the company announced it would acquire ocedurenone – an experimental drug for uncontrolled hypertension and potentially beneficial in treating cardiovascular and kidney diseases – from KBP Biosciences for $1.3 billion. After a failed clinical trial the following year, Novo initiated legal action against KBP alleging that the company misrepresented the drug's effectiveness by concealing unfavorable clinical trial data. Seeking up to $830 million in damages, the Singapore International Commercial Court granted Novo's request for a freeze on KBP's assets and those of its founder, Huang Zhenhua. In November 2023, Novo announced investment of €2.1 billion in a French production facility to increase the production capacity and manufacturing of its popular anti-obesity medication. In February 2024, parent company Novo Holdings agreed to acquire Catalent for $16.5 billion. On completion, Novo said it would acquire three manufacturing facilities from its parent for $11 billion to scale up production to meet the massive demand for Wegovy and Ozempic. In March 2024, Novo reached a $604 billion market capitalization and became the 12th most valuable company in the world. The company's stock jumped to a record high after early trial data showed positive results for its new experimental weight loss pill amycretin. The company also announced it would acquire Cardior Pharmaceuticals and its cardiovascular disease portfolio for up to $1.1 billion.
== Actin remodeling cycle == Cell surface (cortical) actin remodeling is a cyclic (9-step) process where each step is directly responsive to a cell signaling mechanism. Over the course of the cycle, actin begins as a monomer, elongates into a polymer with the help of attached actin-binding-proteins, and disassembles back into a monomer so the remodeling cycle may commence again. The dynamic function of actin remodeling is directly correlated to the immense variability of cell shape, structure, and behavior.
Sources: en.wikipedia.org
=== Alcohol === The removal of ethanol (drinking alcohol) through oxidation by alcohol dehydrogenase in the liver from the human body is limited. Hence the removal of a large concentration of alcohol from blood may follow zero-order kinetics. Also the rate-limiting steps for one substance may be in common with other substances. For instance, the blood alcohol concentration can be used to modify the biochemistry of methanol and ethylene glycol. In this way the oxidation of methanol to the toxic formaldehyde and formic acid in the human body can be prevented by giving an appropriate amount of ethanol to a person who has ingested methanol. Methanol is very toxic and causes blindness and death. A person who has ingested ethylene glycol can be treated in the same way. Half life is also relative to the subjective metabolic rate of the individual in question.
This bonding mode is observed in the commonly available metal carbonyls: Co2(CO)8, Fe2(CO)9, Fe3(CO)12, and Co4(CO)12. In certain higher nuclearity clusters, CO bridges between three or even four metals. These ligands are denoted μ3-CO and μ4-CO. Less common are bonding modes in which both C and O bond to the metal, such as μ3η2.
Phenazopyridine is a medication which, when excreted by the kidneys into the urine, has a local analgesic effect on the urinary tract. It is often used to help with the pain, irritation, or urgency caused by urinary tract infections, surgery, or injury to the urinary tract. In 2023, it was the 275th most commonly prescribed medication in the United States, with more than 800,000 prescriptions.
Cadmium oxide was used in black and white television phosphors and in the blue and green phosphors of color television cathode ray tubes. Cadmium sulfide (CdS) is used as a photoconductive surface coating for photocopier drums.
Sources: en.wikipedia.org
The lyophilized powder is generally stored at -20 °C or lower, desiccated, and protected from light. Solutions are often aliquoted to avoid repeated freeze-thaw cycles. Specific stability data may vary by formulation and purity.
Mass spectrometry is commonly used to confirm molecular mass, while RP-HPLC estimates purity. These methods can be combined with amino acid analysis or NMR for further structural confirmation. A certificate of analysis alone does not guarantee independent verification.
Legality depends on the country and the intended use. In many places it is not approved as a drug and may be regulated as a research chemical. Buyers should check local laws and institutional policies before obtaining it.
Dihexa is a synthetic peptide analog related to angiotensin IV. It is studied in preclinical research for effects on neural signaling and synapse formation. It is not an approved medicine.